Home/Filings/4/A/0000899243-23-016365
4/A//SEC Filing

Blischak Matthew P. 4/A

Accession 0000899243-23-016365

CIK 0001733257other

Filed

Jun 22, 8:00 PM ET

Accepted

Jun 23, 4:30 PM ET

Size

6.5 KB

Accession

0000899243-23-016365

Insider Transaction Report

Form 4/AAmended
Period: 2023-06-09
Blischak Matthew P.
Chief Executive Officer
Transactions
  • Award

    Stock Option (right to buy)

    2023-06-09+962,899962,899 total
    Exercise: $0.27Exp: 2033-06-08Common Stock (962,899 underlying)
Footnotes (2)
  • [F1]On June 9, 2023, the Reporting Person filed a Form 4, which, due to administrative error, inadvertently reported that the reported stock options were granted on June 8, 2023 with a strike price of $0.285, the closing price of the issuer's common stock on such date, and expiration date of June 7, 2033. In fact, as reported in this amendment, the reported stock options were granted on June 9, 2023 with a strike price of $0.271, the closing price of the issuer's common stock on such date, and expiration date of June 8, 2033.
  • [F2]Twenty-five percent (25%) of the shares subject to this option shall vest on June 9, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date.

Issuer

Finch Therapeutics Group, Inc.

CIK 0001733257

Entity typeother

Related Parties

1
  • filerCIK 0001975225

Filing Metadata

Form type
4/A
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 4:30 PM ET
Size
6.5 KB